OTTAWA, Dec. 5 /CNW/ - MDS Nordion, a leading provider of medical
isotopes and radiopharmaceuticals, has provided a further update to their
medical isotope customers about a supply issue at Atomic Energy of Canada
Limited (AECL) that is now expected to extend into January 2008. AECL has
advised MDS Nordion that a further extension of the maintenance shutdown at
the National Research Universal reactor will be required to complete its
upgrade of the electrical back-up system to address a regulatory issue.
AECL is working closely with their regulator, the Canadian Nuclear Safety
Commission, to finalize and complete implementation of their upgrade plan.
Based on the most current information from AECL, we understand that they are
now targeting a return to full production in early to mid-January.
MDS Nordion is concerned with the impact that AECL's supply disruption is
having on customers and patients. As the global leader in the supply of
medical isotopes, MDS Nordion is working closely with its back-up supply
network to mitigate the impact.
Based on this latest update from AECL, the financial impact of this
extended interruption is currently expected to reduce MDS Nordion's adjusted
EBITDA by approximately US $8-9 million in total for the first quarter of
About MDS Nordion
MDS Nordion (www.mdsnordion.com) is a world leader in medical isotopes,
radiation and related technologies. It is a business unit of MDS Inc.
(TSX:MDS)(NYSE: MDZ). MDS Inc. is a global life sciences company that provides
market-leading products and services for the development of drugs and
diagnosis and treatment of disease. We are a leading global provider of
pharmaceutical contract research, medical isotopes for molecular imaging,
radiotherapeutics, and analytical instruments. MDS Inc. has more than 6,200
highly skilled people in 28 countries. Find out more at www.mdsinc.com or by
calling 1-888-MDS-7222, 24 hours a day.
This document contains forward-looking statements. Some forward-looking
statements may be identified by words like "expects", "anticipates", "plans",
"intends", "indicates", "targeted" or similar expressions. The statements are
not a guarantee of future impact or performance and are inherently subject to
risks and uncertainties. The actual impact to the Company of the maintenance
shutdown could differ materially from that currently anticipated due to a
number of factors, including, the actual timing of a return to full production
and other risk factors identified in other documents filed by the Company with
Canadian and US securities regulatory authorities from time to time.
For further information:
For further information: Media: Shelley Maclean, Manager External
Communications, MDS Nordion, (613) 592-3400 ext. 2414,
firstname.lastname@example.org; Investors: Sharon Mathers, Senior Vice-President,
Investor Relations and External Communications, MDS Inc., (416) 675-6777 x